Article Text

PDF
Esmya (ulipristal acetate) - safety update

Statistics from Altmetric.com

The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced temporary safety measures for Esmya (ulipristal acetate) while an EU-wide review investigates the link between the medicine and serious liver injury, including four cases that required liver transplantation.1 Clinicians should not initiate or re-start treatment and should monitor liver function in current and recent users.

Esmya is licensed for use in adult women of reproductive age for pre-operative treatment and for intermittent treatment of moderate to severe symptoms of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.